Zura Bio Limited Class A (ZURA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 28/100 (MEDIUM), 64.4 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 17.04% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- This biotech stock is a top pick at Guggenheim
- Zura Bio to Participate in the Cantor Global Healthcare Conference
- Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation
- One Zura Bio Insider Raised Their Stake In The Previous Year
- Zura Bio (ZURA) Hits Enrollment Milestones As Losses Widen Sharply
- Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
- Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Zura Bio Limited Class A.
Full ZURA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.